• Responsible for the creation and execution of novel ADC projects in Oncology Research pipeline

• Led a team responsible for research of multiple pre-IND and post-IND candidates, research project lead for SGN-35C and SGN-35T• Responsible for non-clinical pharmacology reports and sections of IB and IND• Project lead of pre-IND candidate, led cross functional team towards IND. Worked with team to create and execute development strategy

• Responsible for non-clinical Pharmacology team, ensured delivery of in vivo results to inform pre-clinical and clinical candidates• Oversight of research for multiple pre-clinical projects

• Provided strategic direction of non-clinical pharmacology efforts to determine the therapeutic potential of pipeline candidates including bispecific antibodies, antibody drug conjugates, and immuno-oncology biologics• Led a team of nine scientists and research associates responsible for the design, execution, analysis, and interpretation of all non-clinical pharmacology experiments

• Led Antibody Drug Conjugate Development group of fourteen chemists, conjugation chemists, and biologists responsible for the development of novel antibody drug conjugate technologies and projects• Led ZW49 team, an anti-HER2 biparatopic antibody drug conjugate, advanced cross-functional project from research into development

Head of pharmacology group contibuted to the research and development of bi-specific antibody and antibody drug conjugate projects.

• Discovered mechanism of non-cleavable linker maytansine ADC catabolite exit from the lysosome to the cytoplasm via the lysosomal membrane transporter SLC46A3. • Led AMG 595 project team from early target screen through lead optimization, advanced project from research into development. • Conceived and led ADC technology platform assessment of ten simultaneous pre-clinical research project teams. Created strategy, established deliverables, facilitated and integrated resources for all teams from matrix departments.

• Coordinated Investigational New Drug Application (IND) enabling studies for Adcetris™, an anti-CD30 antibody-drug conjugate including in vivo efficacy, in vitro characterization, and toxicity studies as research team leader.• Discovered role of drug loading on therapeutic index of vcMMAE based antibody drug conjugates.• Designed and executed in vivo efficacy, pharmacokinetics, biodistribution, and toxicity studies to evaluate novel antibody drug conjugates.